The Role of Clinical Pharmacology in Fighting the COVID-19 Pandemic

DRUG DEVELOPMENT TRACK & THERAPEUTIC AREAS OF APPLIED CLINICAL PHARMACOLOGY TRACK

Offers both CME & CPE Credit
UAN #JA4008220-0000-20-010-H01-P
ACPE – 1.5 CONTACT HOURS/KNOWLEDGE-BASED

CO-CHAIR:
Ayyappa Chaturvedula, PhD, Associate Professor, Pharmacotherapy, Univ of North Texas Health Science Ctr
Navin S. Goyal, PhD, Director, Clinical Pharmacology Modeling & Simulation, GlaxoSmithKline plc

TARGET AUDIENCE:
This Symposium will be useful for clinical pharmacologists, physicians, pharmacists and the wider healthcare community.

GOALS & OBJECTIVES:
Following the completion of this activity, the learner will be able to:
1. Describe the clinical pharmacology study design for novel COVID-19 therapies;
2. Evaluate the applications of model-informed drug development in the development of COVID-19 therapies.

Model-informed Drug Development in the COVID-19 Pandemic
Yaning Wang, PhD, Director, Pharmacometrics, Clinical Pharmacology, US Food & Drug Administration

TRV027 as a Potential Treatment for COVID-19
Michael J. Fossler Jr, PharmD, PhD, Vice President, Quantitative Sciences, Trevena Inc

Faculty Panel Discussion, Questions & Answers, Learner Feedback & Evaluation